An experimental cancer “vaccine” showed promising results in a small clinical trial of patients with lymphoma, Angelica LaVito of CNBC reports, citing a study published in the journal Nature Medicine. The results in 11 patients were successful enough to warrant another clinical trial in March on lymphoma patients as well as breast and head-and-neck cancer, reports LaVito. Celldex Therapeutics (CLDX) and Oncovir provided the materials for the clinical trial and the lab work, she adds. Shares of Celldex are up 12c to $4.46 in morning trading
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.